About

Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.

Articles

Magnetic Resonance Angiography Using the Intravascular Contrast Agent Vasovist

Citation:

European Cardiovascular Disease 2006;2(1):1–4

New Insights on Simvastatin and Ezetimibe in a Single Tablet

Citation:

European Cardiovascular Disease 2007;3(1):12–5

Overview to Antihypertensive and Lipid-lowering Therapies and Patient Care

Citation:

US Cardiology 2006;3(2):18–9

Plaque Vulnerability and Related Coronary Event Prediction by Virtual Histology

Citation:

Interventional Cardiology 2006;1(1):17-9